IInbiomotion — Series A (estimated) · €2.2M
This was the second financing round, led by Caixa Capital Risc through its Caixa Innvierte BioMed II vehicle, which is backed by CDTI. Existing shareholders Ysios Capital (through Ysios BioFund I), Fundació Vila Casas and several business angels also took part. The money was to complete clinical validation and regulatory development of the bone-metastasis test within two years. The sources do not name a stage.
LeadCaixa Capital Risc
RoundSeries A (estimated)
Announced9 Mar 2016
CityBarcelona
SectorHealthtech & Bio · Healthtech / Precision oncology diagnostics
Source
W
W
